Medication had allowed older adults with obesity to lower cardiovascular risk to normal-weight levels.
Over three decades, a quiet pharmaceutical revolution reshaped the cardiovascular landscape for older adults living with obesity across seven wealthy nations. A landmark study in The Lancet reveals that by the early 2020s, aggressive prescribing of statins and blood pressure medications had largely erased the once-stark gap in cardiovascular risk markers between obese and normal-weight older adults in countries like England and the United States. Medicine, not weight loss, achieved what public health campaigns could not — though the same protection has yet to reach younger generations, where the gap remains wide and the interventions sparse.
- For decades, obesity reliably predicted worse blood pressure and cholesterol in older adults — that predictive certainty has now been chemically disrupted.
- The convergence is striking: older adults with severe obesity in England and the US now show cardiovascular markers that match or outperform normal-weight peers of the same age.
- The mechanism is pharmaceutical disparity — 70-72% of severely obese older men take cholesterol drugs versus only 40-48% of normal-weight men, a prescribing gap that mirrors the closing risk gap.
- Below age 40, the story inverts entirely — younger adults with obesity remain undertreated and carry elevated cardiovascular risk with little pharmaceutical safety net.
- Researchers and commentators urge caution: erasing one cluster of risk markers is not the same as erasing obesity's broader harms, and integrated prevention must reach younger people before damage accumulates.
For thirty years, researchers tracked a quiet transformation in the cardiovascular health of older adults with obesity. In the 1990s, the pattern was unmistakable — excess weight meant higher blood pressure and worse cholesterol. By the early 2020s, in England and the United States especially, that gap had largely disappeared. Older adults with obesity, even severe obesity, were now showing cardiovascular profiles that matched or sometimes surpassed those of normal-weight peers. The change had nothing to do with weight loss. It was the result of pills.
Published in The Lancet and drawing on nearly one million participants across 110 health datasets in seven high-income countries from 1990 to 2024, the study documents this convergence with precision. The effect was most pronounced in adults aged 60 to 79. The explanation was pharmaceutical: doctors had prescribed statins and blood pressure medications far more aggressively to people with obesity than to those at normal weight. By the early 2020s, roughly 70 to 72 percent of older men with severe obesity in England and the US were taking cholesterol-lowering drugs, compared to 40 to 48 percent of normal-weight men the same age. Study author Majid Ezzati of Imperial College London called it a genuine public health success.
But the story fractures at age 40. Younger adults with obesity showed no such improvement — their cardiovascular risk markers remained elevated, and medication use in this group stayed sparse. Co-author Ysé d'Ailhaud de Brisis warned that cardiovascular risk remains a real threat for obese adults in their twenties and thirties, and that early intervention should not be deferred.
The study's reach is limited to high-income nations with strong pharmaceutical infrastructure, and it could not assess the effects of different medication doses. Yale's Yuan Lu offered a broader caution in commentary: closing the gap in specific risk markers is not the same as eliminating obesity's wider harms — metabolic dysfunction, joint stress, sleep disorders persist untouched by statins. As GLP-1 weight-loss medications enter wider use, this study offers a baseline portrait of what medication alone can and cannot achieve: a genuine cardiovascular victory for older adults, and an unresolved vulnerability for the young.
For thirty years, researchers tracked a quiet shift in the health of older adults carrying extra weight. In the 1990s, the pattern was clear: people with obesity had higher blood pressure and worse cholesterol profiles than their normal-weight peers. By the early 2020s, in countries like England and the United States, that gap had largely vanished. Older adults with obesity—even those with severe obesity—now showed blood pressure and cholesterol levels that matched, or sometimes beat, those of normal-weight people the same age. The change was not because people lost weight. It was because they took pills.
A study published in The Lancet, drawing on nearly one million participants across 110 health datasets in seven wealthy nations from 1990 to 2024, documents this convergence with precision. Researchers examined blood pressure and cholesterol trends in England, the United States, Japan, South Korea, Taiwan, Thailand, and Finland. The findings were most dramatic in the oldest group—people aged 60 to 79. In America and Britain especially, the cardiovascular risk markers that once separated obese from normal-weight older adults had compressed into near-equivalence.
The explanation lies in pharmaceutical uptake. Over three decades, doctors prescribed statins and blood pressure medications far more aggressively to people with obesity than to those at normal weight. By the early 2020s, roughly 70 to 72 percent of older men with severe obesity in England and the United States were taking cholesterol-lowering drugs. Among normal-weight men the same age, the figure hovered around 40 to 48 percent. The medication gap widened with age and severity of weight, and the cardiovascular gap narrowed in lockstep. Majid Ezzati, an author of the study from Imperial College London's School of Public Health, framed it as a public health success: medication had allowed middle-aged and older adults with obesity to lower their cardiovascular risk to levels comparable with people of normal weight.
But the story splits sharply at age 40. Younger adults with obesity showed no such improvement. Their blood pressure and cholesterol remained elevated relative to normal-weight peers, and medication use in this age group remained sparse. The researchers found little evidence of narrowing in the cardiovascular gap for anyone under 40, suggesting that the protective effect of medication was not reaching younger people with obesity. Ysé d'Ailhaud de Brisis, another Imperial College author, warned that cardiovascular health risks persist as a genuine threat for obese adults in their twenties and thirties, and that early intervention—lifestyle changes, screening, and medication when warranted—should not be deferred.
The study carries important caveats. All seven countries were high-income nations with robust pharmaceutical access and healthcare infrastructure. The findings may not apply to low- and middle-income countries, where statins and blood pressure medications remain far less available. Researchers also could not assess the impact of different medication doses, a limitation that leaves some questions about optimal treatment unanswered. A commentary by Yuan Lu of Yale School of Medicine, not involved in the research, offered a broader caution: the convergence of risk factors should not be mistaken for the elimination of obesity-related risk. Medication can blunt some cardiovascular harm, but it does not address the wider health consequences of excess weight—metabolic dysfunction, joint stress, sleep disorders, and others. The real challenge, Lu suggested, lies in integrated prevention that moves beyond treating isolated risk factors one at a time.
As weight-loss medications like GLP-1 agonists become more widely prescribed, the study offers a baseline portrait of cardiovascular health in the population likely to receive them. It shows that older adults with obesity, when medicated, can achieve cardiovascular profiles indistinguishable from normal-weight peers—a genuine achievement of modern medicine. Yet it also exposes a gap: younger people with obesity remain unprotected by the same pharmaceutical interventions, left to face cardiovascular risk without the safety net that age and medication have provided their elders.
Notable Quotes
Taking medication to lower blood pressure and cholesterol has helped middle-age and older adults lower their cardiovascular risk to levels similar to people with normal BMI.— Prof. Majid Ezzati, Imperial College London
The observed convergence in cholesterol and blood pressure levels is largely due to statins and other widely accessible medications—a significant public health success story.— Lakshya Jain, Imperial College London
The Hearth Conversation Another angle on the story
Why did blood pressure and cholesterol levels converge so dramatically in older adults but not younger ones?
It comes down to who gets the pills. Doctors prescribe statins and blood pressure medications much more aggressively to older people with obesity—70 percent of them by the 2020s. Younger people with obesity rarely get those medications, so their risk markers never improved. The medication is doing the work, not weight loss.
So this is a story about pharmaceutical access, not about obesity itself?
Exactly. The study shows that medication can neutralize much of the cardiovascular harm that obesity causes. But it only works if you're old enough and sick enough to get prescribed it. A 35-year-old with obesity doesn't get that protection.
Does that mean the study is good news or bad news?
Both. It's genuinely good news for older adults—they've been protected from heart attacks and strokes through smart medication use. But it's a warning for younger people. The gap in their risk markers never closed, which means they're still vulnerable, and nobody's intervening early.
What about the weight-loss drugs that are becoming popular now?
That's the context the researchers are trying to establish. As GLP-1 drugs roll out, we need to know: what's the cardiovascular baseline for people taking them? This study shows older obese people on statins are actually doing okay. But younger people aren't, and that's where the real problem sits.
Can medication alone solve obesity-related health problems?
No. The commentary makes this clear—medication treats the symptoms, not the disease. Obesity affects joints, metabolism, sleep, multiple organ systems. You can lower someone's blood pressure with a pill, but you haven't addressed why they're carrying the weight or what it's doing to their body overall.
So what should happen next?
Early intervention for younger people. Screening, lifestyle support, medication when appropriate—before they reach 60 and need intensive drug regimens. The study is essentially saying: we figured out how to protect older obese people through medication. Now we need to figure out how to prevent younger obese people from needing that protection in the first place.